Back to results
US 2023/0400468 A1Published application
Human IgG autoantibodies against galactose-deficient IgA1, preparation method thereof, and use thereof
AssigneeNational Defense Medical Center
InventorsShuk-Man KA, Chia-Chao Wu, Ann CHEN
Life of this patent
Estimating the term…
Abstract
The current invention provides high specificity monoclonal antibodies, which can specifically bind to Gd-IgA as a novel non-invasive method for rapid diagnosing of IgAN subjects, which can be applied to unravel the mechanisms of IgA nephropathy and establish therapeutical strategies.
Claims10
A reagent set for detecting the mechanism of IgA nephropathy and establishing a treatment strategy, which comprises an IgG monoclonal antibody.
A method for detecting galactose-deficient O-glycosyl IgA1, comprising:
- (a) obtaining a biological sample from a subject;
- and
- (b) using an IgG monoclonal antibody in an immunoassay to detect galactose deficient O-glycosyl IgA1 in the subject.
A method for diagnosing a subject with IgA nephropathy (IgAN), comprising:
- (a) using an IgG monoclonal antibody in an immunoassay;
- and
- (b) determining whether the antibody binds to galactose-deficient O-glycosyl of IgA1, the binding of the antibody to galactose-deficient O-glycosyl of IgA1 indicating that the subject has or is at risk of developing IgA nephropathy.
Dependencies are inferred from the claim text.